Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Gains from Investment Securities (2016 - 2025)

Pharma-Bio Serv (PBSV) has disclosed Gains from Investment Securities for 12 consecutive years, with -$528746.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities rose 20.04% year-over-year to -$528746.0, compared with a TTM value of -$426283.0 through Oct 2025, changed 0.0%, and an annual FY2023 reading of $343350.0, down 31.33% over the prior year.
  • Gains from Investment Securities was -$528746.0 for Q4 2025 at Pharma-Bio Serv, down from $528746.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $528746.0 in Q2 2025 and bottomed at -$661224.0 in Q4 2024.
  • Average Gains from Investment Securities over 5 years is $126723.9, with a median of $343350.0 recorded in 2023.
  • The sharpest move saw Gains from Investment Securities plummeted 292.58% in 2024, then rose 20.04% in 2025.
  • Year by year, Gains from Investment Securities stood at $470000.0 in 2021, then rose by 6.38% to $500000.0 in 2022, then tumbled by 31.33% to $343350.0 in 2023, then tumbled by 292.58% to -$661224.0 in 2024, then grew by 20.04% to -$528746.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for PBSV at -$528746.0 in Q4 2025, $528746.0 in Q2 2025, and -$661224.0 in Q4 2024.